Patients with chronic kidney disease (CKD) are at an increased risk not only for end-stage kidney disease (ESKD) but also for cardiovascular disease (CVD). In this review article, we summarize the current evidence of CKD as a high-risk condition for CVD based on reports from Japan and other countries to draw attention to the close clinical association between CKD and CVD. Several epidemiologic studies have shown that the presence of CKD and reduced renal function are independent predictors of CVD also in Japan. According to a post-hoc analysis of CASE-J, the power of CKD as a predictor of CVD is as strong as diabetes mellitus and a previous history of ischemic heart disease. CKD worsens classical risk factors including hypertension and dyslipidemia, and dyslipidemia is associated with increased thickness and stiffness of large arteries independent of major confounders. A post-hoc analysis of MEGA indicates that lipid-lowering therapy with statins reduces the risk of CVD, and that it appears to be more efficacious in patients with than without CKD. These reports from Japan and other countries suggest that CKD should be regarded as a high-risk condition comparable to diabetes mellitus, and that strict control of dyslipidemia would be beneficial in preventing CVD, at least early stages of CKD.
, long-term and repeated hemodialysis treatment was previously considered as one of the major causes of the increased CVD risk 3) ; however, the presence of microalbuminuria is an independent predictorofCVD 4) ,andtheriskforCVDincreasesin a stepwise manner during the course of progressive loss of renal function 5) .Thus, chronic kidney disease (CKD), rather than dialysis treatment itself, is now consideredahigh-riskconditionforCVD 6) . Such recognition has generated clinical practice guidelinesespeciallyforthosewithCKD,suchasthe
Introduction
Statisticsindicateasteadyincreaseinthenumber of patients with end-stage kidney disease (ESKD) needing renal replacement therapy including dialysis. According to the preliminary report by the Japanese SocietyforDialysisTherapy(JSDT) more than three months 9, 12) . Kidney damage is defined as pathologic abnormalities or markers of damage, including abnormalities in blood or urine testsorimagingstudies.EstimatedGFR(eGFR)can becalculatedbyformulasthatarebasedontheserum creatinineconcentration,age,andgender,forspecific ethnicgroups.JSNestablishedtheeGFRformulafor Japanese 13) .CKDisfurtherdividedinto5stagesbased onthepresenceofalbuminuriaorproteinuriaandthe reductionofGFR 14) ( Table 1) .Accordingtothisclassification system, dialysis patients with ESKD are diagnosed as CKD stage 5D. Also, the definition of CKD is used irrespective of the diagnosis of kidney disease.ThissimpledefinitionofCKDenablesusto dealwithetiologicallydifferentkidneydiseases,aswell as dialysis patients and kidney transplant recipients, usingthesameplatform.Inaddition,thishasfurther facilitatedclinicalandepidemiologicalresearch.
Kidney Disease: Improving Global Outcome (KDIGO) has recently published the revised version of the staging system of CKD 15) . In the new definition, CKD stages are defined by the combination of GFR(G1throughG5)andalbuminuria(A1through A3).Inaddition,previousCKDstage3(eGFR30-59 mL/min/1.73 m 2 ) is divided into G3a (eGFR 45-59 mL/min/1.73 m 2 ) and G3b (eGFR 30-44 mL/min/ 1.73 m 2 ); however, no change is made in the cut-off levels of GFR ＜60 mL/min/1.73 m 2 or the urinary albumin to creatinine ratio＞30 mg/g in diagnosing CKD.
Fig. 1 depicts the conceptual natural history of CKD.The risk for developing CVD increases as the stage of CKD advances; therefore, the CKD stages European Best Practice Guidelines (EBPG) 7) and the Clinical Practice Guidelines by the National Kidney Foundation(NKF)KidneyDiseaseOutcomeQuality Initiative(K/DOQI) 8) inUSA.Recently,theJapanese Society of Nephrology (JSN) published the "Clinical Practice Guidebook for the Diagnosis andTreatment of Chronic Kidney Disease 2007" 9) and "EvidencebasedClinicalPracticeGuidelinesforthetreatmentof CKD 2009" 10) to help all categories of health care providers who take care of CKD patients. Generally, these clinical practice guidelines recommend strict control of risk factors for CVD, including dyslipidemia;however,thecurrent2007versionofthe"Clinical Practice Guidelines for the Prevention of AtheroscleroticDisease"bytheJapanAtherosclerosisSociety (JAS) 11) doesnotmentiontheelevatedriskofCVDin patients with CKD, although patients with diabetes mellitus are considered an especially high-risk subgroupinwhomstrictcontroloflow-densitylipoproteincholesterol(LDL-C)isrecommended.
The purpose of this article is to summarize the evidencefromJapanandothercountriesthatCKDis animportantriskfactorforCVD.Also,wereviewthe role of dyslipidemia in the elevated CVD risk in CKD. Comparison of the above clinical practice guidelineswillhelptodeterminehowtomanagedyslipidemiainCKD.
Definition, Natural History and Clinical Significance of CKD
CKD is defined as either kidney damage or a glomerularfiltrationrate(GFR)＜60mL/min/m 2 for infarction)wasincreasedby57%per10timesincrease intheurinaryalbumin/creatinineratio.Verylowlevels of albuminuria ( ≥ 4.8 μg/min) were associated with an increased risk of developing coronary heart disease (HR, 2.0; 95%CI, 1.4-3.0) after adjustment for otherrelevant risk factorsin 2762participants of theThirdCopenhagenCityHeartStudy 19) . Reduced GFR is an important predictor of CVD. In the Atherosclerosis Risk in Communities (ARIC) study including 15350 subjects 5) , reduced GFRwaslinearlyassociatedwithanincreasedriskfor atherosclerotic CVD (ASCVD) outcomes. Each 10 mL/min/1.73 m 2 lower GFR was associated with an adjusted HR of 1.05 (95%CI, 1.02-1.09), 1.07 (95%CI, 1.01-1.12), and 1.06 (95%CI, 0.99-1.13) forASCVD,denovoASCVD,andrecurrentASCVD, respectively.Inthe5-yearfollow-upof27,998subjects in the US 20) , the rate of renal replacement therapy (RRT) including dialysis and transplantation was 1.1%,1.3%,and19.9%,respectively,forCKDstages 2,3,and4,respectively.Bycomparison,themortality rate in 5 years was 19.5%, 24.3%, and 45.7% for CKDstages2,3,and4,respectively.ThisstudyindicatesthatCKDpatientsaremorelikelytodiebefore starting RRT. According to the statistical report 21) in 1120295 adults within a large, integrated system of indicate not only the severity of kidney disease, but also the risk for CVD. This scheme was developed based on previous and recent epidemiological evidence,asreviewedbelow.
Epidemiology of CKD and CVD in Western Countries
Thepresenceofproteinuriaisassociatedwithan increasedriskforCVD,asshownbymanystudies.In the 5209 men in the Framingham study 16) , the hazardsratios(HRs)fortotalmortalityandcardiovascular mortality were 2.9 (95% confidence interval, CI, 2.0-4.2) and 1.7 (95%CI, 1.0-2.9), respectively. In a cohort of 216 diabetic patients in Denmark 17) , those withhigherlevelsofalbuminuriahadanHRof2.94 (95%CI, 1.31-6.64) for mortality as compared to those with lower levels of albuminuria. The risk of deathfromeitherCVDornon-CVDlinearlyincreased against log-transformed urinary albumin concentrationamong40548inhabitantsofthecityofGronin-gen,theNetherlands 4) .Intheobservationalcohortof 8206non-diabetichypertensivepatientswithleftventricular hypertrophy who participated in the LIFE study 18) , the risk for the composite endpoint (death fromCVD,nonfatalstroke,andnonfatalmyocardial 22) . Among the 14857 volunteers in the USA (ARIC study), excluding those with congestive heart failure 23) , the risk of the combination of hospitalizationandmortalityduetoheartfailurewashigherfor those with reduced eGFR ＜60 mL/min/1.73 m 2 as compared with those with eGFR＞90 mL/min/1.73 m 2 (HR1.94,95%CI,1.49-2.53).Anotherreportof theARICstudy 24) showedthattheriskofdeveloping symptomatic stroke was independently predicted by CKDasdefinedbyeGFR＜60mL/min/1.73m 2 (HR, 1.22; 95%CI, 1.02-1.44) and by increased systolic blood pressure (HR, 1.18; 95%CI, 1.14 to 1.21 per 10-mmHg rise). Interestingly, however, individuals withCKDhadaJ-shapedrelationshipbetweenstroke outcomesandsystolicbloodpressure(SBP)suchthat thosewithSBP＜120mmHghavesignificantlyhigher riskthanindividualswithCKDandSBPbetween120 and129mmHg.SuchaJshapewasnotseeninindividualswithoutCKD. TheamountofalbuminuriaanddecreasedeGFR synergistically increases the risk for CVD 21) . In a cohortof10640participantsof"TheActioninDiabetes and Vascular disease: preterAx and diamicroN-MR Controlled Evaluation" (ADVANCE) study, the riskforCVDwasevaluatedinrelationtothebaseline urinary albumin-to-creatinine ratio (ACR) and eGFR 25) . During the average follow-up of 4.3 years, 938cardiovasculareventsoccurred.Themultivariateadjusted HR for CVD events was 2.48 (95% CI, 1.74-3.52)forevery10-foldincreaseinbaselineACR, and 2.20 (95% CI, 1.09-4.43) for every halving of baseline eGFR. There was no significant interaction between the effects of higher ACR and lower eGFR. PatientswithbothACR＞300mg/gandeGFR＜60 mL/minper1.73m 2 atbaselinehada3.2-foldhigher riskforcardiovasculardiseases.
Epidemiology of CKD and CVD in the Japanese General Population
These reports consistently indicate that the risk ofCVDisincreasedinthepresenceofCKDinWesterncountries. 30) showed the synergistic effects of reduced eGFR and proteinuria on the risk for CVD. In a 10-year profrom the Hisayama Study, showing that CKD increases the risk of myocardial infarction in men, whereasitincreasestheriskofstroke(ischemicstroke) inwomen.
Nakamuraet al.reportedtheassociationbetween CKDanddeathfromCVDamong7316participants of NIPPON DATA90 29) . After adjusting for major risk factors, as compared with normal eGFR (＞90 
Impact of CKD on CVD as Compared with that of Other Risk Factors
Yasunoet al. 34) performedapost-hocanalysisof dataof1447hypertensivepatientswhoparticipatedin theCandesartanAntihypertensiveSurvivalEvaluation inJapantrial(CASE-J).TheycomparedtheHRsfor CVDbetweenCKDandotherestablishedriskfactors (Fig. 2) .CVDwasdefinedascompositecardiovascular events including sudden death, cerebrovascular events, cardiac events, vascular events including dissectingaorticaneurysmandperipheralarterialdisease, andrenalevents(serumcreatinine≥ 4.0mg/dL,doublingofserumcreatinine,orend-stagerenaldisease). During the mean follow-up period of 3.3 years, 87 composite CVD events were reported, including 10 renal events. In a multiple Cox regression model, CVD events showed the strongest association with renal dysfunction as defined by proteinuria and/or serum creatinine ≥ 1.3 mg/dL with HR(95%CI) of 2.82(1. 18-4.39 
Epidemiology in CKD stage 5D
AccordingtothereportfromUSAin1998 2)
,the spective cohort study of 30764 men and 60668 women aged 40-79 years, both the presence of proteinuria and the reduction of eGFR ＜60 mL/ min/1.73m 2 werepredictorsofcardiovascularorallcause death. The risk of CVD death was two-fold higherinmenand4-6-foldhigherinwomeninthose withbothproteinuriaandreducedeGFRascompared withthosewithoutproteinuriaandreducedeGFR.
OtherobservationalstudiesfromJapan 31, 32) also provide additional evidence that CKD is a high-risk conditionforCVD.
Meta-Analysis of Studies in the General
Populations Worldwide ChronicKidneyDiseaseProgressionConsortium performedacollaborativemeta-analysisof21general populationcohortsfromWesternandAsiancountries including Japan, Korea, Taiwan, and China 33) . In studies with ACR including 105872 participants (730577 person-years), reduced eGFR was associated with an increased risk of all-cause and cardiovascular mortality. ACR was also associated with an increased risk of all-cause and cardiovascular mortality. eGFR and ACR were multiplicatively associated with a risk of mortality without evidence of interaction. Similar findingswererecordedinstudieswithurinaryprotein dipstick measurements including 1128310 participants (4732110 person-years).This large-scale metaanalysis has established that reduced eGFR and increased ACR independently and synergistically increasetheriskofworseoutcomes. Hazardsratioforeachvariableisadjustedfortheothervariablesinthefigure.ThisfigurewasdevelopedbytheauthorsbasedontheoriginalpaperbyYasunoet al. 34) emiasecondarytoCKDcanbediscussedseparatelyin proteinuria-dominantCKDandreducedGFR-dominantCKD( Table 4) . Nephroticsyndromeisarepresentativecondition forthefirstgroupofpatients 38) .Thehepaticproduction of very low density lipoprotein (VLDL) is elevated because of a nonspecific increase in protein secretionbythelivertocompensateforhypoalbuminemia caused by massive loss of serum proteins into urine.VLDLismetabolizedintolowdensitylipoprotein (LDL) by the action of lipoprotein lipase (LPL) inperipheraltissues.UrinarylossofapoC-Ⅱ,anactivatorofLPL,coulddecreaseLPLaction,resultingin impaired catabolism of TG-rich lipoproteins into LDL.Thus,thelipoproteinphenotypesinthiscondition vary among typeⅡa (increased LDL), typeⅡb (increased LDL and VLDL), and type Ⅳ (increased VLDL),dependingonthedegreeofLPLsuppression. HDL-C is reported to be unchanged or reduced in human nephrotic syndrome 38) . Reduction of plasma HDL-Cmaybeexplainedtosomeextentbytheloss ofα-migratinglipoproteinsintourine 39) . Thesecondgroupofpatientshavechronicrenal failure 40) . HepaticVLDL production is not increased in renal failure, whereas the degradation of TG-rich lipoproteins is impaired 41) . Post-heparin plasma LPL activityisreportedtobenormalordecreased,whereas post-heparin plasma LPL protein mass is not relativeriskforCVDdeathinmiddle-agedhemodialysispatientswasintherangeof10to30ascompared withthegeneralpopulation,andamuchhigherrelativeriskwasshownforyoungerpatients.
InJapan,therelativeriskofdeathfromischemic heartdiseasewas9.3to23.3timeshigherfordialysis patientsthanthegeneralpopulationagedbetween30 and74yearsin1993 35) .Were-calculatedtherelative risk of death from CVD in Japanese patients with CKDstage5DascomparedwiththeJapanesegeneral population based on the more recent report by JSDT 36) andthenationalstatistics 37) in2005 (Table 3) . Dialysispatientsshowed6.0to17.1timeshigherrisk ofdeathfromischemicheartdiseasethanthegeneral populationinthesameagecategories.Althoughthese figures are somewhat lower than previously, it is important to note that the relative risk of ischemic heartdiseaseforCKDstage5Dismuchhigherthan forearlystagesofCKD.Furthermore,inCKDstage 5D,therelativerisksofdeathfromstrokeandcongestiveheartfailurearemuchhigherthanfromischemic heartdisease.
Dyslipidemia in CKD
CKD is an important condition that results in secondarydyslipidemia.SinceCKDisdefinedbythe presenceofproteinuriaand/orreducedGFR,dyslipid- hadasignificantextentofcoronaryarterystenosisevidenced by angiography. Interestingly, when the incident dialysis patients were followed-up for 2 years, only4%ofpatientsexperiencedmajorcardiacevents (MACE)amongthosewithoutcoronaryarterydisease atthestartofdialysis.Incontrast,about50%patients experienced MACE within 6 months among those who had coronary artery disease at the initiation of dialysis 50) .Thesestudiesindicatethatthedevelopment ofclinicalischemicheartdiseaseafterstartingdialysis is due mostly to advanced coronary atherosclerosis thatdevelopedbeforestartingdialysis.
Angiographic studies are difficult to perform in pre-dialysis patients with CKD; however, atherosclerotic changes can be evaluated by measuring arterial wall thickness using ultrasound, and by measuring arterial stiffness using a pulse wave analyzer. Carotid arterial intima-media thickness (IMT) was significantlyincreasedinpatientsundermaintenancehemodialysistherapy 51) ,butthiswasnotfullyexplainedby dialysis treatment, because a comparable increase in IMTwaspresentinpre-dialysispatientswithCKD 52) . Also, IMT was not correlated with the duration of hemodialysis. Aortic pulse wave velocity (PWV) was increasedinmaintenancehemodialysispatients 53) ,But thiswasalsonotfullyexplainedbydialysistreatment, because there was a comparable increase in aortic PWV in pre-dialysis patients with CKD 54) . Aortic PWVwasnotcorrelatedwiththedurationofhemodialysis. In a recent report from Italy 55) , the annual increase of the cross-sectional area of carotid atheroscleroticplaquewashigherinCKDpatientswithCCr of 29-50 mL/min than in those with CCr of 20-29 decreased 42) . Patients with renal failure have an increased serum concentration of apoC-Ⅲ 43) , an inhibitor of LPL, as well as increased apoC-Ⅲ/C-Ⅱ ratio. Also, patients with renal failure show marked reductionofhepatictriglyceridelipase(HTGL)activityandHTGLproteinmassinpost-heparinplasma 42) . DecreasedHTGLexplainstheaccumulationofIDL 44) andnormalLDLsize 45) inrenalfailure.Themosttypical lipoprotein phenotype in renal failure is type Ⅳ with decreased high density lipoprotein cholesterol (HDL-C) 43) .Inaddition,apreviousstudyusingagarose gel electrophoresis 43) reported that as much as 23%ofhemodialysispatientsshowedabroadβpat-ternorthepresenceofamid-bandbetweentheβand pre-βpeaks,indicatingahighprevalenceofremnant accumulationandtypeⅢ-likephenotypeinthispopulation. Possible mechanisms for decreased HDL-C are low activity of lecithin:cholesterol acyltransferase (LCAT), and enhanced lipid transfer between HDL andaccumulatedVLDLparticles.
Dislipidemia is worsened when both CKD and diabetesmellitusarepresentatthesametime.Among diabeticpatients,thepresenceofnephropathyisassociated with increased VLDL and IDL, as well as decreased HDL 46) . Similar impacts of diabetes and CKDhavebeenfoundinacomparisonofhemodialysispatientswithandwithoutdiabetesmellitus 47) .
Atherosclerotic Arterial Changes in CKD and Role of Dyslipidemia
Two studies from Japan 48, 49) show that more than50%ofCKDpatientsstartingdialysistreatment 
Traditional and Non-Traditional Risk Factors for CVD in CKD
TheriskofCVDdeathiselevatedinthosewith CKD,particularlyinthosewithCKDstage5D.Sarnak et al. 6) listed the candidates of traditional and non-traditional risk factors that may explain the increased risk of CVD in CKD.Traditional risk factors are older age, male sex, hypertension, higher LDL-C, lower HDL-C, diabetes mellitus, smoking, physical inactivity, menopause, family history of CVD,andleftventricularhypertrophy.Theyalsoproposednontraditionalriskfactorssuchasalbuminuria, homocysteine, lipoprotein(a), apolipoprotein(a) isoforms, lipoprotein remnants, anemia, abnormal calcium/phosphate metabolism, extracellular fluid overload,electrolyteimbalance,oxidativestress,inflammation(elevatedCRP),malnutrition,thrombogenicfactors,sleepdisturbances,andalterednitricoxide/endothelinbalance. Someexpertshaveproposedthehypothesisthat malnutritionandinflammationpromoteatherosclerosis (MIA syndrome) 64) in dialysis patients; however, themarkersofmalnutritionwerenotassociatedwith theriskofincidentCVD,butwiththeincreasedrisk of fatality after incident CVD as shown in the study byJSDT 63) .Wespeculatethatsomelistednon-traditional risk factors may be factors associated with increasedfatality.
Lipid-Lowering Treatment and Risk for CVD in Early Stages of CKD
There are several post-hoc analyses of large randomizedcontrolledtrials(RCTs)thatcalculatedtherisk reductionwithstatininsubjectswithCKD( Table 5 ). In such subanalyses of the Heart Protection Study (HPS) 65) , ASCOT-LLA 66) and Pravastatin Pooling Project (PPP) 67) , using simvastatin, atorvastatin and pravastatin,respectively,theriskofCVDwassignificantly reduced. Very interestingly, the relative risk reductionwasgreaterinthesubgroupwithCKDthan mL/min, suggesting more rapid plaque growth in CKD stage 3 and slowed progression in later stages. These data are in agreement with the above studies usingcoronaryangiography 48, 49) ,indicatingthatatherosclerotic changes are advanced in the pre-dialysis periodofCKD.
Regarding the role of dyslipidemia in advanced atherosclerosis in patients with CKD, both carotid IMT 52, 56) and aortic PWV 53, 54, 57) are reported to be positively associated with non-high-density lipoprotein cholesterol (non-HDL-C), independent of other risk factors in subjects with various degrees of CKD. Amongnon-HDLlipoproteins,IDLshowedtheclosest association with aortic PWV in hemodialysis patients 53) .Thesestudiessupportthenotionthatdyslipidemia plays an important role in promoting atherosclerosisinCKD.
Reverse Epidemiology between Cholesterol and Death from CVD
Alowerlevelofserumtotalcholesterolisknown topredictahigherriskofall-causemortalityinhemodialysis cohorts 58) .This is also true when death from CVDwastakenasanendpoint 59) .SincehypercholesterolemiaisanestablishedriskfactorforCVDinthe general population, this strange relationship between deathriskandtheriskfactorofCVDiscalled'reverse causality', 'reverse epidemiology' 60) , or 'cholesterol paradox' 61) . Importantly, in these studies reporting a paradoxicalassociation,theendpointsarenotincident CVD,butdeathfromCVDordeathfromall-cause. In addition, no adjustment is performed for possible confounderssuchasadvancedage,nutritionalstatus, and inflammation. Since death from CVD occurred only when a subject experienced incident CVD and thendied,theriskfactorsofCVDdeathmaybedifferentfromthoseofincidentCVD 61, 62) .
Non-HDL-C as an Independent Predictor of Incident Atherosclerotic CVD in CKD
A recent observational cohort study by JSDT 63) examined the relationship between serum lipids and incident CVD among 45390 hemodialysis patients. Afteradjustmentforage,sex,diabetesmellitus,dialysis vintage, body mass index, serum albumin and C-reactive protein (CRP) levels, the risk of incident myocardial infarction was positively associated with non-HDL-C and inversely with HDL-C.This result is similar to the epidemiology in the general population.Interestingly,amongthosewhoexperiencednew CVDincludingmyocardialinfarction,cerebralinfarc-greater benefit with lipid-lowering treatment with statinsthanthosewithnormalkidneyfunction.
Lipid-Lowering Treatment and Risk for CVD in CKD Stage 5D
ThereareonlythreeRCTswithstatinsinCKD as the primary target population. The first is die Deutsche Diabetes Dialyse Studie (4D, the German Diabetes Dialysis Study) that enrolled 1255 patients withtype2diabetesmellitustreatedwithhemodialy-sis 71) .Thestudyexaminedtheeffectof20mgperday ofatorvastatinversusaplaceboonthecompositeendpoint of CVD death, nonfatal myocardial infarction andnonfatalstrokeforthemeanfollow-upperiodof 4 years. Although LDL-C was reduced by 40%, the 8% reduction in the primary composite endpoint in the atorvastatin arm was not statistically significant. ThemeanbaselineLDL-Cwas126mg/dL. in overall study subjects. In a meta-analysis 68) , treatmentwithfluvastatinsignificantlyreducedtheriskfor combinedcardiacdeathandmyocardialinfarctionby 41%ascomparedwithaplacebointhesubgroupwith creatinineclearance(CCr)＜50mL/min,therelative riskreductionbeinggreaterthan30%inthesubgroup withCCr≥ 50mL/min.Furthermore,thesub-analysis of MEGA in Japan 69) , pravastatin treatment reduced the risk for coronary heart disease, stroke, combined CVDevents,andtotalmortalityby48%,73%,54% and52%,respectivelyascomparedwithdiettherapy alone. The relative risk reductions in CKD patients weremuchbetterthanintotalsubjects.ArecentsubanalysisofCARDS 70) ,atrovastatinreducedtheriskfor MACEby42%includinga61%reductioninstroke in type 2 diabetic patients with CKD stage 3. AlthoughCKDwasnottheprimarytargetpopulation in the above studies, these post-hoc analyses strongly suggest that CKD is a subpopulation that may have . SHARP enrolled 6274 patients not on dialysis and 3023 patients on dialysis.The patients not on dialysis met theinclusioncriteriaofserumcreatininelevels≥1.7 mg/dL in men and ≥1.5 mg/dL in women and the meaneGFRwas23mL/min/1.73m 2 atbaseline,corresponding to CKD stage 4. The intervention was simvastatin20mgperdayplusezetimibe10mgper day versus a placebo control. The mean follow-up ThesecondstudyisAURORA 72) ,whichenrolled 2776patientstreatedwithdialysisincludingbothdia-betic and nondiabetic patients.The intervention was 10 mg per day of rosuvastatin versus a placebo control.Thesubjectswerefollowed-upforamedianof3.8 years. Although both LDL-C and C-reactive protein levels were decreased in the rosuvastatin group, the 4% reduction in the composite primary endpoint in the rosuvastatin arm was not statistically significant. ThemeanbaselineLDL-Cwas99mg/dL.
These 'negative' results of 4D and AURORA may be disappointing, but these results may indicate that the initiation of statin treatment is not effective inreducingCVDriskinpatientswithaveryadvanced stageofCKDhavinglowtonormallevelsofbaseline LDL-C.Inarecentpost-hocanalysisof4D 73) ,März et al. found that atorvastatin treatment significantly reduced CVD risk in subjects in the highest quartile of baseline LDL-C (＞145 mg/dL). The HRs (95% CI)were0.69(0.48-1.00)forthecompositeprimary 2 diabetes mellitus did not significantly reduce the risk of the primary endpoint (coronary heart disease deathornon-fatalmyocardialinfarction),whereasthe treatmentwasassociatedwithlessprogressionofalbuminuria.
Clinical Practice Guidelines for Lipid Management in CKD (Table 7) In 2001, the National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) Ⅲ published guidelines that recommend decreasing LDL-C below 100 mg/dL in adults with ischemic heartdiseaseandthosewithequivalentrisk 85) .Following the NCEP ATP Ⅲ guidelines, European Renal Association-EuropeanDialysisTransplantation(ERA-EDTA) published guidelines on the management of dyslipidemiainpatientswithCKD 7) in2002.Inthe followingyear,theNationalKidneyFoundationKidney Disease Outcome Quality Initiative (NKF K/ DOQI)releasedguidelinesfordyslipidemiainCKD 8) . These guidelines specific for patients with CKD recommend controlling LDL-C below 100 mg/dL because of the very high risk for CVD in these patients,particularlypatientsondialysis.Inthe"Evidence-basedClinicalPracticeGuidelinesforthetreatment of CDK 2009" 10) , JSN proposed a recommendation to control LDL-C below 120 mg/dL in patientswithCKD.Also,LDL-Cbelow100mg/dLis recommended if possible. Recently, JSDT published clinical practice guidelines regarding the evaluation andtreatmentofcardiovascularcomplicationsindialysispatients 86) .TheJSDTguidelinesrecommendcontrollingLDL-Cbelow120mg/dLforprimarypreventionandbelow100mg/dLforsecondaryprevention. Alternative goals are non-HDL-C below 150 mg/dL and130mg/dLusingnon-fastingbloodsamples.No recommendations are mentioned on TG or HDL-C in the above four guidelines for CKD patients. The EuropeanSocietyofCardiology(ESC)andtheEuropean Atherosclerosis Society (EAS) have published guidelines for the management of dyslipidemia, and the ESC/DAS guidelines 87) recommend achieving LDL-C＜1.8mmol/L(＜70mg/dL)inpatientswith CKDstage2-4basedontherecognitionthatCKDis CADriskequivalent.
Conclusions
The risk of death from CVD is elevated in patients with CKD, and the risk is higher in more advanced stages of CKD. The impact of CKD on incident CVD is as large as that of type 2 diabetes periodwas4.9years.Thekeyoutcomewasacomposite of major atherosclerotic events (coronary death, myocardialinfarction,non-hemorrhagicstroke,orany revascularization). The simvastatin plus ezetimibe group showed a significantly lower risk of the major atherosclerotic events with HR (95%CI) of 0.83 (0.74-0.94).Whenthesubjectsweredividedintodialysis and non-dialysis subgroups, the risk reduction ratewas20%innon-dialysispatientsand9%indial-ysis patients, although no significant heterogeneity wasnoticedbetweennon-dialysisanddialysispatients (p = 0.25).
Possible Reno-Protective Effects of Lipid-Lowering Treatment
Lipid-loweringtreatmentsmaydecreaseproteinuriaandincreaseormaintainrenalfunction(CCrand eGFR). Observational cohort studies 75) showed that dyslipidemia is an independent predictor of the decline of renal function. Lipid-lowering with statins wasreportedtodecreasealbuminuriaandproteinuria in observational 76) and controlled trials 77) . A metaanalysis 78) showed that statin treatment is associated withdecreasedACRascomparedwithaplacebo.LDL apheresis with LDL adsorption columns was also reportedtodecreaseproteinuriaandurinarylossesof glomerularepithelialcells(podocytes) 79) . Statin treatment is associated with increased eGFRorCCrascomparedwithaplaceboinpot-hoc analysesofprimary 69, 70) andsecondarypreventiontrials with statin 80, 81) . Studies performed in Japan also provided similar results. A higher dose of statin was associatedwithamoreimpressiveincreaseofeGFRin a post-hoc analysis of the Treating To New target trial 81) . Some studies indicate that the increase in eGFR was greater in subjects with lower eGFR at baseline. A meta-analysis 78) supports the notion that statins protect against the decline of renal function. Increased eGFR was also reported for Japanese patientswithhypercholesterolemia 69, 82) . Endo et al. 83) reported that treatment with probucol, a lipid-lowering agent with potent anti-oxidative property, delayed the progression of diabetic nephropathy in their study including 102 patients with overt albuminuria of ACR＞300 mg/gCr who werefollowed-upforof3yearsorlonger.Theprobucolgroupshowedasmallerincreaseinproteinuriaand longertimetodialysisinitiation,suggestingreno-protectiveeffectsofpurobucol.
Fibrates may have beneficial effects on the kidneys. According to the FIELD study 84) , treatment withfenofibrate(200mgdaily)inpatientswithtype mellitus and pre-existing ischemic heart disease. Patients with CKD often have risk factors of death fromCVDincludingbothtraditionalandnon-traditionalriskfactors.Amongthetraditionalriskfactors, dyslipidemia is modifiable. BecauseTG-rich lipoproteins(VLDLandIDL)areincreasedinCKD,particularlyinadvancedstages,non-HDL-Cmaybeabetter index for dyslipidemia than LDL-C in this population.Lipid-loweringtreatmentwithstatinsiseffective inreducingtheriskforCVDinearlystagesofCKD, whereasthebenefitofsuchmedicationmaybelimited to those with an elevated level of LDL-C in patients withCKDstage5D.
Thus,inouropinion,CKDshouldberegarded asanimportantsubgroupofpatientsathighriskfor CVD. The target levels for LDL-C or non-HDL-C shouldbesetlowerinCKDasahigh-riskpopulation. Further information is needed to develop individualized recommendations for patients with different stagesofCKD. Abbreviations: TG, triglycerides; LDL-C, low-density lipoprotein cholesterol; Non-HDL-C, non-high-density lipoprotein cholesterol; HDL-C, high-densitylipoproteincholesterol;EBPG,EuropeanBestPracticeGuidelines;K/DOQI,KidneyDiseaseOutcomeQualityInitiative;JSN,JapaneseSocietyofNephrology;JSDT,JapaneseSocietyforDialysisTherapy;NM,notmentioned.
